Although clinical trials of BACE1 inhibitors conducted to date have been discontinued due to inefficacy or safety reasons, BACE1 remains an effective therapeutic target for AD (Hampel et al., 2021), and researchers should examine whether BACE1 intervention can play a role in seizures in AD patients. Here, BACE1 is linked to Alzheimer disease.